Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study.
Yung-Tai ChenShu-Chen KuoPei-Wen ChaoYea-Yuan ChangPublished in: PloS one (2019)
Neither statins nor fibrates provide clinical benefit superior to that achieved with standard anti-tuberculosis treatment. Future clinical trials should investigate the effects of statins and fibrates on short-course standard anti-TB therapy.
Keyphrases
- mycobacterium tuberculosis
- clinical trial
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- hiv aids
- peritoneal dialysis
- pulmonary tuberculosis
- randomized controlled trial
- type diabetes
- patient reported outcomes
- replacement therapy
- combination therapy
- study protocol
- phase ii
- patient reported